A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Adjuvant durvalumab Sponsors: ETOP IBCSG Partners Foundation; AstraZeneca AG Switzerland Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study | Switzerland Health